Related Experiment Video

Updated: May 24, 2026

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data
07:17

MEDUSA for Identifying Death Regulatory Genes in Chemo-genetic Profiling Data

Published on: February 7, 2025

The role of genetics in drug dosing

Nicholas Ware1

  • 1Renal Department, Great Ormond Street Hospital for Children, Great Ormond Street, London, WC1N 3JH, UK. nicholasware@doctors.org.uk

Pediatric Nephrology (Berlin, Germany)
|February 24, 2012
PubMed

Insights

Renal transplantation is the best therapy for kidney failure. Pharmacogenetics can personalize immunosuppression, improving graft survival and reducing rejection by predicting drug responses.

Area of Science:

  • Nephrology
  • Immunology
  • Pharmacology

Background:

  • Renal transplantation is the preferred renal replacement therapy.
  • Graft rejection and achieving optimal immunosuppression are significant challenges.
  • Standard dosing and therapeutic drug monitoring have limitations in predicting drug response.

Purpose of the Study:

  • To explore the role of pharmacogenetics in optimizing immunosuppression after renal transplantation.
  • To investigate how genetic screening can improve predictions of drug pharmacodynamics and pharmacokinetics.
  • To assess the potential of pharmacogenetics in enhancing long-term graft outcomes.

Main Methods:

  • Utilizing genetic screening (pharmacogenetics) to predict individual metabolic responses to immunosuppressive drugs.
  • Integrating pharmacogenetic data with pharmacokinetic and pharmacodynamic principles.
  • Comparing outcomes with standard dosing and therapeutic drug monitoring.

Main Results:

  • Pharmacogenetics enables more accurate prediction of drug pharmacodynamics and pharmacokinetics.
  • Personalized immunosuppression based on genetic profiles can be achieved.
  • Potential for improved graft survival and reduced rejection episodes.

Conclusions:

  • Pharmacogenetics offers a promising approach to personalize immunosuppression in renal transplant recipients.
  • This strategy has the potential to significantly improve graft outcomes by mitigating rejection.
  • Integrating pharmacogenetics into clinical practice could revolutionize post-transplant care.

More Related Videos

Assessing Specificity of Anticancer Drugs In Vitro09:39

Assessing Specificity of Anticancer Drugs In Vitro

Published on: March 23, 2016

Related Concept Videos

Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...